Chen Franco-Yehuda Net Worth

Chen Franco-Yehuda biography

Chen Franco-Yehuda serves as Chief Financial Officer, Treasurer, Secretary of the Company. Mrs. Franco-Yehuda served as the Company’s Head of Accounting and Financial Reporting since July 2016 and, prior to that, the Company’s Controller since May 2013. Before joining the Company, from October 2008 to April 2013, Mrs. Franco-Yehuda served as a manager of audit groups relating to public and private companies in various industries at PricewaterhouseCoopers (PwC) and also as a lecturer of accounting classes at the Open University of Israel from 2009 to 2014. Mrs. Franco-Yehuda holds a bachelor’s degree in economics and accounting from Haifa University, and is a certified public accountant in Israel.

What is the salary of Chen Yehuda?

As the Chief Financial Officer, Treasurer и Secretary of Pluri Inc, the total compensation of Chen Yehuda at Pluri Inc is $207,690. There are 3 executives at Pluri Inc getting paid more, with Yaacov Yanay having the highest compensation of $612,604.

How old is Chen Yehuda?

Chen Yehuda is 37, she's been the Chief Financial Officer, Treasurer и Secretary of Pluri Inc since 2019. There are 7 older and no younger executives at Pluri Inc. The oldest executive at Pluri Inc is Mark Germain, 69, who is the Independent Director.

What's Chen Yehuda's mailing address?

Chen's mailing address filed with the SEC is MATAM PARK, BUILDING #5, , HAIFA, L3, 3508409.

Insiders trading at Pluri Inc

Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman и Israel Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.

What does Pluri Inc do?

Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a

Pluri Inc executives and stock owners

Pluri Inc executives and other stock owners filed with the SEC include:

• Yaacov Yanay,
  Pres, CEO & Director
• Zalman Aberman,
  Executive Chairman of the Board
• Yaky Yanay,
  President, Chief Executive Officer, Director
• Chen Franco-Yehuda,
  Chief Financial Officer, Treasurer, Secretary
• Dana Rubin,
  Director of Investor Relations
• Moria Kwiat,
  Independent Director
• Mark Germain,
  Independent Director
• Isaac Braun,
  Independent Director
• Doron Shorrer,
  Lead Independent Director
• Dr. Nitsan Halevy M.D.,
  Chief Medical Officer
• Efrat Livne-Hadass,
  VP of HR
• Lior Raviv,
  Chief Technology Officer
• Israel Ben Yoram,
  Director
• Nachum Rosman,
  Director
• Hava Meretzki,
  Director
• Erez Egozi,
  Chief Financial Officer
• Shai Pines,
  Director
• Boaz Gur Lavie,
  CFO
• Wolf Capital Limited Part...,
  10% owner
• Maital Shemesh Rasmussen,
  Director
• Rami Avraham Levi,
  Director
• Pinhas Doron Birger,
  Director
• Varda Shalev,
  Director
• Zami Aberman,
  Director